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Abstract: Hereditary inclusion body myopathy-2 (HIBM2) is an adult-onset, muscular disease caused by mutations in the 
GNE gene. HIBM2-associated GNE mutations causing hyposialyation have been proposed to contribute to reduced muscle 
function in patients with HIBM2, though the exact cause of this disease is unknown. In the current studies we examined 
pre-clinical in vivo toxicity, and expression of the plasmid-based, CMV driven wild-type GNE plasmid vector. The plasmid 
vector was injected intramuscularly (IM) or systemically (IV) into BALB/c mice, following encapsulation in a cationic 
liposome (DOTAP:Cholesterol). Single IM injections of the GNE-lipoplex at 40 μg did not produce overt toxicity or deaths, 
indicating that the no observable adverse effect level (NOAEL) dose for IM injection was 40 μg. Single intravenous (IV) 
infusion of GNE-lipoplex was lethal in 33% of animals at 100 μg dose, with a small proportion of animals in the 40 μg 
cohort demonstrating transient toxicity. Thus the NOAEL dose by the IV route was greater than 10 μg and less than or equal 
to 40 μg. Real-time RT-qPCR analysis demonstrated recombinant human GNE mRNA expression in 100% of muscle tissues 
that received IM injection of 40 μg GNE-lipoplex, at 2 weeks. These results indicate that GNE-lipoplex gene transfer is 
safe and can produce durable transgene expression in treated muscles. Our ﬁ  ndings support future exploration of the clinical 
efﬁ  cacy of GNE-lipoplex for experimental gene therapy of HIBM2. 
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Introduction
Hereditary inclusion body myopathy-2 (HIBM2) or distal myopathy with rimmed vacuoles (DMRV) 
is an autosomal, recessive, muscular disorder that is caused by mutations in the GNE gene.
1–3 It is an 
early adult-onset disease characterized by slowly progressive distal and proximal muscle weakness and 
atrophy. There is preferential weakness of the tibialis anterior muscles with relative sparing of quadri-
ceps. Histologically, it is characterized by cytoplasmic rimmed vacuoles in atrophic ﬁ  bers and cyto-
plasmic or nuclear ﬁ  lamentous inclusions composed of tubular ﬁ  laments.
4
HIBM2 has been attributed to a variety of homozygous or compound heterozygous missense mutations 
in the GNE gene, spanning the entire enzyme including either the epimerase or kinase domains or both. 
The mutation spectrum is varied, with over 40 mutations found across the whole coding region of the 
GNE gene.
5 Cases of HIBM2 conﬁ  rmed by genetic testing have been found all over the world.
6–8
The GNE gene encodes the bifunctional enzyme uridine diphospho-N-acetylglucosamine 
(UDP-GlcNAc) 2 epimerase/N acetyl-mannosamine (ManNAc) kinase (GNE/MNK).
9,10 This enzyme 
is ubiquitously expressed and catalyzes the ﬁ  rst 2 steps of the sialic acid biosynthesis pathway.
11 HIBM2-
associated GNE mutations have been shown to result in reduced activity of both GNE and MNK which 
is responsible for reduced sialic acid production.
12,13 Sialyation of skeletal muscle glycoproteins is 
necessary for proper folding, stabilization, and function of these proteins.
14–16 GNE mutations resulting 
in hyposialyation of muscle glycoprotein has been proposed to contribute to myoﬁ  brillar degeneration 
and reduced muscle function in patients with HIBM2, although yet undeﬁ  ned factors may also contribute 
to the pathology of HIBM2.
2,14,16–18
Since reduction in sialic acid due to the GNE mutation is considered to be one of the causal factors 
in the development of HIBM2, we sought to reconstitute wild-type (wt) GNE expression using a gene 90
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therapy approach. We constructed a GNE-wt-DNA 
vector using human GNE cDNA and pUMVC3 
expression vector. Our earlier in vitro ﬁ  ndings 
indicated that this vector produced high levels of 
recombinant GNE protein in transfected CHO-Lec3 
(GNE deﬁ  cient cell line) cells that produced low 
levels of sialic acid.
19 To characterize its in vivo 
activity, the GNE expression vector was 
complexed with a cationic liposome (composed of 
1,2-Dioleoyl-3-Trimethylammonium-Propane 
(DOTAP) and cholesterol) to form a 300–500 nm 
lipoplex (GNE-lipoplex). Complexing DNA with 
liposomes has been demonstrated to extend the life 
span of circulating DNA. Prior studies have shown 
that naked plasmid DNA rapidly degrades in vivo, 
but lipoplexes could be detected hours after 
injections.
20
Toxicity studies were performed in mice to 
delineate preclinical parameters applicable for the 
design of clinical trials with the GNE-lipoplex. 
Additionally, we assessed GNE expression via 
real time RT-qPCR analysis following both intra-
muscular (IM) and intravenous (IV) delivery of 
GNE-lipoplex.
Materials and Methods
Study animals
Male and female BALB/c mice (9–11 weeks) 
were purchased from Harlan Sprague Dawley 
(Indianapolis, Indiana) and housed in an animal 
facility approved by the Institutional Animal Care 
and Use Committee at Baylor Research Institute 
(Dallas, Texas). The animals were grouped into 
different cohorts for either a single IM or IV 
injection as outlined in Table 1. Studies I and III 
were performed to assess the toxicity proﬁ  le of 
GNE-lipoplex and examine recombinant human 
GNE (rGNE) mRNA in various mice tissues. 
Study II was performed to examine temporal 
expression of rGNE mRNA in mouse muscle 
tissue. For Studies I and III mice were observed 
for 2 weeks at which time surviving mice were 
sacriﬁ  ced for gross examination and collection of 
various tissues for rGNE mRNA expression and 
histopathology analysis.
GNE cloning
The parental vector containing wild type human 
GNE cDNA was provided by Daniel Darvish 
(HIBM2 Research Group; Encino, CA). The 
destination vector, pUMVC3, was purchased from 
Aldevron (Fargo, ND). Wild type GNE was cloned 
from the parent vector into pUMVC3 via Eco RI 
restriction digest, gel puriﬁ  cation, and T4 ligation. 
All pUMVC3-GNE clones were sequenced by 
Seqwright (Houston, TX) in both orientations to 
conﬁ  rm the vector identity. Positive pUMVC3-GNE 
clones were shipped to the Waisman Clini-
cal BioManufacturing Facility, University of 
Wisconsin-Madison for master cell bank and large 
scale GMP production.
Preparation of lipoplexes
Stock 5x DOTAP:Cholesterol liposomes were 
purchased from GeneExcel (Houston, TX) and 
diluted to 2x in D5W. Plasmid DNA was diluted 
in D5W to a concentration of 1mg/ml. An equal 
volume of diluted plasmid DNA was mixed with 
the diluted DOTAP:Cholesterol to form the 
GNE-lipoplex (0.5 mg/ml). For studies I and III, 
GNE- lipoplex was diluted in D5W to a ﬁ  nal 
concentration of 0.5, 0.2, 0.125, and 0.05 mg/ml 
so that the animals were injected with an equal 
volume of material. Empty liposomes were 
prepared by diluting stock DOTAP:Cholesterol in 
D5W to a ﬁ  nal concentration of 1x. Prepared 
GNE-lipoplex was stored in glass vials with argon 
gas at 2–8 °C, until used. The GNE-lipoplex had 
an average size of 400 nm and a zeta potential 
of +55 mv. Animals were injected with GNE-
lipoplexes within 2 weeks of lipoplex formulation. 
(After three months, stability studies on remaining 
GNE-lipoplexes demonstrated no significant 
change in lipoplex structure.) For study II, the 
vials containing GNE-lipoplex were warmed to 
room temperature and mixed with 20% (v/v) 0.2 
um ﬁ  ltered India ink, prior to injection. The ﬁ  nal 
injected test article contained 80% GNE-lipoplex 
and 20% dye.
Animal injections
Glass vials containing GNE-lipoplex were brought 
to room temperature and loaded into 1 ml syringes 
using a 21-gauge needle to reduce disruption of 
the complexes. The needle was changed to a 
30-gauge needle prior to injecting the animals. For 
Study I, mice were administered a single IM injec-
tion of 0 μg, 10 μg, or 40 μg GNE-lipoplex in a 
total volume of 80 μl. Mice were lightly anesthe-
tized using isoﬂ  urane inhalation and injected in the 91
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right quadriceps muscle twice, each injection 
consisting of 40 μl GNE-lipoplex. This precaution 
was taken to prevent injury to the muscle tissue. 
For Study II, India ink was ﬁ  ltered though a 0.2 μm 
ﬁ  lter and mixed (20% v/v) with GNE-lipoplex prior 
to loading the syringes so that the injected material 
could be tracked at the time of necropsy. The IM 
injections were performed as mentioned earlier, 
for Study I. In Study III, mice were administered 
10 μg, 40 μg, or 100 μg of GNE-lipoplex as a 
single IV injection in a total volume of 200 μl. All 
three studies included mice that were injected with 
“empty” liposomes without DNA (vehicle control), 
with Study I also containing uninjected control 
mice (Table 1).
Toxicology assessments
Mice were monitored daily for adverse events and 
for evidence of overt toxicity. Mice were weighed 
prior to treatment and once a week for 2 weeks 
after treatment (studies I and III). On day 14 post- 
injection, surviving mice in Studies I and III were 
sacriﬁ  ced by cervical dislocation following isoﬂ  u-
rane vapor inhalation. Necropsy was performed to 
assess pathological changes. Blood and sera were 
shipped to SRI laboratories (Mountain View, CA) 
for evaluation of complete blood counts and blood 
chemistry proﬁ  le. The following parameters were 
considered for toxicology analysis: alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), creatine kinase, blood urea nitrogen, total 
bilirubin, albumin, alkaline phosphatase, WBC, 
RBC, and platelet counts.
The various tissues collected at necropsy, 
including left uninjected muscle, right injected 
muscle (only for study I), kidney, spleen, liver, and 
lungs (Studies I and III), were weighed and divided 
into 2 pieces each. One tissue piece was snap fro-
zen in liquid nitrogen for molecular analysis. The 
2nd tissue piece was embedded in a mold contain-
ing optimum cutting temperature (OCT) mounting 
medium and snap-frozen in liquid nitrogen. The 
frozen tissue blocks were sectioned at 4 μm thick-
ness and stained with hematoxylin and eosin. The 
stained slides were shipped to IDEXX Laboratories 
(West Sacramento, CA) for histopathology analy-
sis by a certiﬁ  ed veterinary pathologist. For Study 
II, spleen, injected, and uninjected muscles were 
collected from the mice at 24 hr, 48 hr, 72 hr, week 
1 and 2 post-injection. These tissues were pro-
cessed to quantify expression of rGNE mRNA via 
real-time RT-qPCR.
Table 1. Study design.
Study 
number
Injection route GNE-Lipoplex 
dose (total 
volume injected)
Treatment Mice/cohort Assessment
I Intramuscular 10 μg (80 μl) GNE-lipoplex 6 female, 
6 male
Safety and 
toxicology, 
40 μg (80 μl) GNE-lipoplex 6 female, 
6 male
GNE expression
0 μg (80 μl) Empty liposomes 6 female, 
6 male
No injection _ 6 female, 
6 male
II Intramuscular 40 μg (80 μl) GNE-lipoplex 15 female GNE expression
0 μg (80 μl) Empty liposomes 6 female
III Intravenous 10 μg (200 μl) GNE-lipoplex 6 female, 
6 male
Safety and 
toxicology, 
40 μg (200 μl) GNE-lipoplex 6 female, 
6 male
GNE expression
100 μg (200 μl) GNE-lipoplex 6 female, 
6 male
0 μg (200 μl) Empty liposomes 6 female, 
6 male92
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RT-qPCR analysis
Total RNA was isolated from the mouse samples 
by tissue homogenization with the Fast-Prep 
24 (MP Biomedical, Solon, OH) and total RNA 
extracted using the Corbett X-tractor robot (San 
Francisco, CA) along with the Macherey-Nagel 
(Bethlehem, PA) NucleoSpin-8 RNA kit. One 
microgram of total RNA was used as starting mate-
rial for cDNA synthesis using oligo dT primers and 
the BioRad (Hercules, CA) iScript Select kit. GNE 
speciﬁ  c primers were designed so that only the 
plasmid (human GNE) transcript would be ampli-
ﬁ  ed without cross reacting with the endogenous 
(mouse GNE) mRNA.
Statistical analysis
Group means/average and standard deviations were 
calculated for body weights, hematology, and 
blood chemistry assays. Student’s t-test (p  0.05) 
was used to analyze statistical differences among 
cohorts.
Results
No observable adverse effect level (NOAEL) 
determination for a single IM injection
In order to establish safety of a localized injection 
of GNE-lipoplex, a single 10 μg or 40 μg dose 
was administered IM into normal, immunocom-
petent BALB/c mice. Mice administered with 
either 10 μg or 40 μg GNE-lipoplex survived 
without demonstrating overt signs of toxicity for 
the observation period of 2 weeks (Table 2). Treat-
ment induced weight loss was not evident in 
injected mice when compared to their baseline 
weights (mean weight of female mice in grams; 
Table 2. Toxicology assessments of mice injected with a single, intramuscular injection of GNE-lipoplex.
Uninjected (n = 12) 0 μg (n = 12) 10 μg (n = 12) 40 μg (n = 12)
Survival 12/12 12/12 12/12 12/12
Treatment induced body 
weight decrease
0/12 0/12 0/12 0/12
Acute toxicity (rufﬂ  ed coat, 
hunched posture), mice 
recovered in 48 hours after 
injection
0/12 0/12 0/12 0/12
Lesions at necropsy 0/12 0/12 0/12 0/12
Lesions observed by 
histopathology caused by 
treatment
0/12 0/12 0/12 0/12
Bone marrow function Uninjected (n = 4) 0 μg (n = 5) 10 μg (n = 2) 40 μg (n = 5)
WBC (× 10
3/μL) 3.44 ± 1.47 2.58 ± 0.88 2.35 4.38 ± 1.5
RBC (× 10
6/μL) 8.44 ± 0.65 7.79 ± 0.73 8.81 8.43 ± 0.75
Platelets (× 10
3/μL ) 520.75 ± 374.78 396.2 ± 343.05 569.50 428.2 ± 346.31
Serum chemistry Uninjected (n = 6) 0 μg (n = 6) 10 μg (n = 6) 40 μg (n = 6)
AST (U/L) 172 ± 42 305 ± 65* 323 ± 271 141 ± 88
ALT (U/L) 50 ± 11 61 ± 12 58 ± 18 41 ± 17
Total bilirubin (mg/dL) 0.1 0.1 0.1 0.1
Alkaline phosphatase (U/L) 94 ± 17 95 ± 17 97 ± 13 96 ± 18
Creatine kinase (U/L) 1052 ± 290 2110 ± 571* 2349 ± 2507 948 ± 851
BUN (mg/dL) 20 ± 4 22 ± 3 24 ± 9 17 ± 4
Albumin (g/dL) 3.1 ± 0.2 3.1 ± 0.2 3.4 ± 0.2 3.1 ± 0.2
*p  0.05 compared to uninjected cohort.93
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pre-treatment: 17.9 ± 1.1, week 1 post treatment: 
18.4 ± 1.1, week 2 post-treatment: 19 ± 1.1; mean 
weight of male mice in grams; pre-treatment: 
25.9 ± 1.3, week 1 post treatment: 26.5 ± 1.4, 
week 2 post-treatment: 26 ± 2.8).
There were no signiﬁ  cant differences in the 
various hematology parameters for the 3 injected 
cohorts at the end of 2 weeks after exclusion of 
clotted specimens from the various cohorts 
(Table 2). Blood chemistry analyses, showed sig-
niﬁ  cantly elevated AST and creatine kinase values 
in mice that received the “empty” liposomes 
injection (mice that received 0 μg DNA in 
liposomes) (AST: 305 ± 65 U/L; creatine kinase: 
2110 ± 571 U/L; n = 6) as compared with the unin-
jected cohort (AST: 172 ± 42 U/L; creatine kinase: 
1052 ± 290 U/L; n = 6). This suggested toxicity to 
the liver and muscles of mice in this cohort due to 
the empty liposomes. The average AST and cre-
atine kinase levels in the 10 μg cohort appeared 
elevated when compared to the uninjected control 
group, but these values were not statistically sig-
niﬁ  cant due to the high standard deviation as a 
result of 2 outliers in the 10 μg group (p = 0.2 for 
AST and creatine kinase assay). AST and creatine 
kinase levels were not signiﬁ  cantly elevated in 
cohorts that received 40 μg GNE-lipoplex (p = 0.5 
and p = 0.8 respectively) (Table 2) suggesting that 
the elevated values observed for the 10 μg cohort 
were not due to GNE-lipoplex.
Although the albumin levels were altered in the 
cohort injected with 10 μg (3.4 ± 0.1 g/dL) as com-
pared with the uninjected cohort (3.1 ± 0.2 g/dL), 
these values were within the normal range for the 
assay (Table 2). There were no signiﬁ  cant altera-
tions in ALT, total bilirubin, alkaline phosphatase 
and blood urea nitrogen levels among the various 
cohorts (Table 2).
None of the organs (liver, lung, spleen, kidney, 
or muscles) demonstrated any gross pathological 
changes at necropsy. Muscle inflammation or 
degeneration was observed in 4 mice in the cohort 
injected with liposome only, and in 1 mouse that 
was uninjected. Myodegeneration with or without 
myositis was observed in 1 mouse in the cohort 
injected with 10 μg, and 6 mice in the cohort 
injected with 40 μg GNE-lipoplex. Overall, 
histopathological analysis did not demonstrate 
any remarkable findings that could be attrib-
uted to GNE-lipoplex treatment. The observed 
myodegeneration and associated tissue mineraliza-
tion with myositis (4 mice) or without myositis 
(8 mice) was probably related to injection site 
trauma among 36 IM injected mice. These ﬁ  ndings 
indicate that the no observed adverse effect level 
(NOAEL) dose for a single IM injection was 40 μg 
GNE-lipoplex.
Recombinant human GNE (rGNE) mRNA 
expression analysis after IM injection
Human rGNE mRNA expression in the injected, 
necropsied muscle tissue was determined by 
RT-qPCR analysis, using total RNA (300–2500 ng/μl) 
extracted from tissues. An equal amount of total 
RNA (1 μg) was converted to cDNA via reverse 
transcription. rGNE mRNA expression was 
detected in 50% (6/12) of mice at the 10 μg dose 
in the injected muscle, and in 83% (10/12) of mice 
at the 40 μg dose. Mean rGNE mRNA expression 
in the injected muscle was 8.8E + 04 fg at the 10 μg 
dose and 4.3E + 04 fg at the 40 μg dose (Fig. 1b). 
There was no detectable rGNE mRNA expression 
in animals that received the “empty” liposome, or 
in the contra-lateral muscle (uninjected) or the 
major organs (liver, lung, spleen, or kidney) of 
mice that were injected with the GNE-lipoplex 
(Fig. 1a).
Follow-up analysis using a tracking dye (India 
Ink) allowed the identiﬁ  cation of human rGNE 
mRNA expression in all the GNE-lipoplex injected 
animals. Animals were injected with 40 μg 
GNE-lipoplex mixed with India Ink, and rGNE 
mRNA expression examined at various times 
(24 hr, 48 hr, 72 hr, weeks 1 and 2 post IM injec-
tion, 3 animals per time point). The injected 
muscle was identiﬁ  ed by its dye uptake from 24 hr 
up to 2 weeks post-injection. Consistent with 
the earlier study, rGNE mRNA expression was 
detected for up to 2 weeks post-injection, and 
exclusively distributed in 100% of the injected 
muscle tissue in all animals. There was no rGNE 
mRNA expression detected in the uninjected 
muscle or spleen at any time post-injection. 
Recombinant GNE mRNA expression pattern in 
the injected muscle was robust at 24 hours post 
injection (9.3E + 05 fg rGNE mRNA per gram 
muscle), and detectable levels of GNE were 
reduced over time (9.0E + 04 fg rGNE mRNA per 
gram muscle, Fig. 2). Expression levels at 2 weeks 
post IM injection were comparable between the 
initial study (4.3E + 04 fg rGNE mRNA per gram 
of muscle, Fig. 1b) and the follow-up study (Fig. 2), 
with the slightly lower expression level in the 94
Phadke et al
Gene Regulation and Systems Biology 2009:3   
0 μg
A
v
g
 
r
G
N
E
 
m
R
N
A
 
(
f
g
)
 
p
e
r
 
i
n
j
e
c
t
e
d
m
u
s
c
l
e
 
(
g
)
40 μg
Dose
1.0E + 03
1.0E + 04
1.0E + 05
1.0E + 06
K
i
d
n
e
y
N
o
n
-
I
n
j
e
c
t
e
d
 
m
u
s
c
l
e
L
u
n
g
L
i
v
e
r
G
N
E
-
I
n
j
e
c
t
e
d
 
m
u
s
c
l
e
5
e
-
4
n
g
 
G
N
E
-
w
t
 
(
s
t
a
n
d
a
r
d
)
5
e
-
6
n
g
 
G
N
E
-
w
t
 
(
s
t
a
n
d
a
r
d
)
S
p
l
e
e
n
10 μg
A)
B)
Figure 1. Recombinant human GNE mRNA expression post intramuscular injection. Mice were administered a single IM injection of 0 μg, 
10 μg, or 40 μg GNE-lipoplex. At the end of 2 weeks, tissues (non-injected muscle, injected muscle, kidney, spleen, liver, and lungs) were 
collected. Total RNA was extracted and real-time qPCR analysis was performed. A) rGNE mRNA expression and distribution. Plasmid DNA 
(GNE-wt) was diluted and used as a template to demonstrate the sensitivity of the assay. A representative gel picture illustrates rGNE was 
only detected in injected muscles from study I. B) Mean (± SD) rGNE mRNA expression in injected muscles (n = 12).95
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initial study attributed to sampling variance of the 
injected muscle tissue.
NOAEL determination for a single IV injection
In order to determine safety for a single IV injection 
of GNE-lipoplex, mice were injected either with 
10 μg, 40 μg, or 100 μg GNE-lipoplex, and their 
survival monitored for 2 weeks. Three of 12 mice 
in 100 μg GNE-lipoplex cohort died within 
24 hours after injection and 1 mouse died at 
48 hours post-injection (Table 3 and Fig. 3). The 
remaining eight mice in the 100 μg GNE- lipoplex 
cohort (2 females, 6 males) and 2 female mice in 
40 μg GNE-lipoplex cohort showed acute toxicity 
(rufﬂ  ed coat, hunched posture) within 24 hr of IV 
injection, but recovered within 48 hours. There 
were no subsequent adverse events noted during 
the 2-week observation period for the surviving 
mice in all cohorts (Table 3). Treatment induced 
weight loss was not evident in injected mice 
when compared to their baseline weights (mean 
weight of female mice in grams; pre-treatment: 
17.9 ± 1.1, week 1 post treatment: 18.5 ± 1.1, week 2 
post-treatment: 19 ± 1.1; mean weight of male mice 
in grams; pre-treatment: 26.2 ± 1.3, week 1 post 
treatment: 26.1 ± 1.5, week 2 post-treatment: 
26.9 ± 1.6).
Complete blood count analysis did not indicate 
any signiﬁ  cant differences among the various 
hematology parameters examined in the 4 cohorts 
at 2 weeks post-injection (Table 3), after exclusion 
of preparation-related clotted specimens from the 
various cohorts. There was no remarkable differ-
ence in blood chemistry among sera of all 4 
cohorts at 2 weeks post-injection (Table 3). Aver-
age AST and creatine kinase levels for the 10 μg 
cohort appeared slightly elevated when compared 
to the 0 μg cohort, but these values did not reach 
statistical signiﬁ  cance (p = 0.09 for AST assay 
and p = 0.08 for creatine kinase assay) due to the 
high standard deviation as a result of a single 
outlier in the group. AST and creatine kinase 
levels were not signiﬁ  cantly elevated in cohorts 
that received 40 μg or 100 μg GNE- lipoplex 
(p  0.05) (Table 3) suggesting that the elevated 
values observed for the 10 μg cohort were not due 
0
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Figure 2. Recombinant human GNE mRNA expression in injected muscles over time. Mice were administered 40 μg GNE-lipoplex, IM and 
sacriﬁ  ced at different time points. Tissues (injected muscle, non-injected muscle, and spleen) were harvested and processed for RT-qPCR 
analysis. Recombinant human GNE mRNA was detected exclusively in the injected muscle. Mean (± SD) rGNE mRNA expression in the 
injected muscle (n = 3 at each time point). The regression line illustrates a steady decrease of recombinant human GNE mRNA expression 
over time.96
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to GNE-lipoplex. Albumin levels were reduced in 
the cohorts injected with either 40 μg or 100 μg 
of GNE-lipoplex (3.2 ± 0.2 g/dL). However, these 
values were within the normal range for the assay 
(Table 3).
There were no gross pathological changes 
observed in the liver, kidney, lungs, or spleen 
harvested from necropsied mice from the 4 cohorts. 
Histopathological evaluations did not demonstrate 
inflammatory lesions, or evidence of necrosis. 
There was also no indication of any severe degen-
erative change in the tissues. In view of the transient 
behavioral toxicity observed in mice that received 
the 40 μg dose, the NOAEL dose was determined 
to be 10 μg and 40 μg GNE-lipoplex for a 
single IV injection.
Recombinant human GNE (rGNE) mRNA 
expression analysis after IV injection
To characterize human rGNE expression post-
intravenous infusion, total RNA was extracted from 
spleen, lung, liver, and kidney 2 weeks post IV 
injection. Muscles were not harvested because 
expression was not expected to be detected beyond 
96 hours post injection, based on previous 
studies.
21,22 Analysis of qPCR data suggest a dose-
dependent expression of the GNE-transgene based 
on the number of mice (n = 12 except for n = 8 for 
the 100 μg cohort) expressing detectable rGNE 
mRNA and the amount of rGNE mRNA expressed 
per tissue (Figs. 4a,b). Recombinant GNE mRNA 
was not detected in control treatment cohort. At 
the 100 μg dose, at least 75% of the animals had 
detectable levels of rGNE in all tissues, with a 
majority of the expression located in the liver and 
lung, as expected based on ﬁ  ndings from other 
groups.
23
Discussion
The pathologic mechanism for muscle ﬁ  ber degen-
eration is not clear. Reduced availability of sialic 
acid, due to GNE mutations leading to hyposiay-
lation of muscle proteins is proposed to be a key, 
if not a sole factor responsible for muscle degen-
eration in HIBM2.
14,17,18 Our current study dem-
onstrates that recombinant human GNE mRNA 
could be expressed from a wt-GNE plasmid vector 
in vivo. This approach was found to be safe when 
GNE-lipoplex was administered as a single IM 
or IV injection up to 40 μg. These ﬁ  ndings were 
supported by 100% survival in IM injected mice 
and the lack of hematology, blood chemistry, or 
histopathological abnormalities up to the maximum 
tested dose of 40 μg. As a result, the NOAEL for 
IM dosing was considered to be 40 μg. In view 
of the observed transient toxicity at 40 μg dose, 
the NOAEL for IV administration was considered 
to be 10 μg and 40 μg.
Previous studies have shown that acute toxicity 
is dose dependant on DNA-lipoplexes.
24–26 These 
studies demonstrated that naked DNA or empty 
liposomes had little toxic effect, but the DNA-
lipoplex was toxic at high doses. This toxicity was 
a result of the lipoplex, and not the speciﬁ  c DNA 
payload. Morbidity within 48 hours was primarily 
due to severe liver damage, apoptosis of endothe-
lial cells in the lung, and systemic release of 
proinﬂ  ammatory cytokines. Intravenous injections 
containing 100 μg
27 or 80 μg
28 DNA-lipoplex 
lead to acute toxicity, which is in accordance with 
our IV ﬁ  ndings with the 100 μg injected cohort. 
Although the maximum IM injection volume in 
humans will vary depending on the muscle size 
and location, several hospitals follow the guideline 
of 1cc in the deltoid or 4cc in large muscles, such 
as the gluteus.
29 For comparison purposes, an 
injection of 20 ul (10 ug) in a 20 g mouse is 
equivalent to 80 mls (40 mg) in an 80 kg human. 
For clinical trials, initial IM injection volumes 
would be signiﬁ  cantly lower to reduce possible 
tissue damage due to large volumes of injected 
material. Results for these studies adequately cover 
the safe, maximum dose that can be injected into 
human muscle.
Although the target tissue for gene therapy of 
HIBM2 is skeletal muscle, there is signiﬁ  cant 
muscle loss in patients with the disease.
30 The 
limited mass of the affected muscle makes IM 
injections difﬁ  cult, due to the limited volume that 
can be administered. An intravenous infusion of 
the GNE-lipoplex would address the issue of not 
having enough tissue mass for injections. Previous 
studies by Templeton et al. have demonstrated 
distribution of DNA-lipoplexes (similar to the ones 
used for the current animal study), to all major 
organs, including skeletal muscles.
31 In those 
studies, lung was the primary target tissue, with 
skeletal muscle demonstrating approximately 1.5 
logs less reporter gene expression. Our study was 
comprised of a single IM or IV injection to dem-
onstrate the effectiveness of our GNE-lipoplex 
delivery and safety. Studies are currently underway 
to detect the trafﬁ  cking of sialic acid to determine 97
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if organs such as the liver can excrete labeled sialic 
acid for uptake in distant organs such as skeletal 
muscle. Future studies, including administration 
of GNE-lipoplexes via multiple injections are 
being planned to determine expression proﬁ  le of 
the GNE transgene and observe any toxicity due 
to re-administration of the lipoplex.
Attempts to produce mouse models to study 
the pathophysiological mechanism of the disease 
have proved to be difﬁ  cult. A limb girdle muscular 
dystrophy hamster model was generated and 97% 
of the animals were rescued in muscle strength 
following a single IM injection with an adeno-
associated virus (AAV) containing δ-sarcoglycan 
(SG) gene.
32 However, generation of GNE 
deﬁ  cient mice by inactivation of UDP-GlcNAc 
2-epimerase led to embryonic lethality.
33 
Although heterozygous GNE deﬁ  cient mice were 
viable and demonstrated 25% reduction in 
membrane bound sialic acid, these mice did not 
develop myopathy even after 2 years.
34 Generation 
of knock-in mice harboring the M712T GNE/MNK 
mutation led to the development of homozygous 
mutant mice pups that did not survive beyond the 
3rd day after birth and demonstrated renal abnor-
malities and podocytopathy 2 days after birth.
35 
The recent report by Malicdan et al. (36) created 
transgenic GNE 
(−/−) mice expressing the human 
GNE mutation D176V. These mice exhibited some 
similar biochemical defects as afﬂ  icted patients 
(hyposialyation, beta-amyloid deposition, 
rimmed vacuole formation) at 32 weeks, but the 
pathological features of this transgenic model 
(involvement of involuntary muscles, high expres-
sion levels of the mutant GNE gene in skeletal 
muscles) were not consistent with the human 
Table 3. Toxicology assessments of mice injected with a single, intravenous injection of GNE-lipoplex.
0 μg (n = 12) 10 μg (n = 12) 40 μg (n = 12) 100 μg (n = 12)
Survival 12/12 12/12 12/12 8/12
Treatment induced body 
weight decrease
0/12 0/12 0/12 0/12
Acute toxicity (rufﬂ  ed 
coat, hunched posture), 
mice recovered in 
48 hours after injection
0/12 0/12 2/12 8/12
Lesions at necropsy 0/12 0/12 0/12 0/12
Lesions observed by 
histopathology caused 
by treatment
0/12 0/12 0/12 0/12
Bone marrow function 0 μg (n = 6) 10 μg (n = 4) 40 μg (n = 4) 100 μg (n = 3)
WBC (× 10
3/μL) 4.13 ± 0.65 5.2 ± 0.73 4.56 ± 1.09 2.7 ± 0.1
RBC (× 10
6/μL) 8.65 ± 0.65 8.61 ± 0.76 8.92 ± 0.11 8.48 ± 0.45
Platelets (× 10
3/μL) 623.33 ± 430.04 970 ± 378 882.75 ± 270.11 792 ± 374.2
Serum chemistry 0 μg (n = 6) 10 μg (n = 6) 40 μg (n = 6) 100 μg (n = 4)
AST (U/L) 102 ± 19 144 ± 52 119 ± 28 88 ± 30
ALT (U/L) 48 ± 11 45 ± 12 39 ± 14 39 ± 4
Total bilirubin (mg/dL) 0.1 0.1 0.1 0.1
Alkaline phosphatase 
(U/L)
101 ± 14 104 ± 24 100 ± 22 101 ± 19
Creatine kinase (U/L) 455 ± 122 776 ± 390 542 ± 131 387 ± 220
BUN (mg/dL) 20 ± 5 19 ± 4 17 ± 3 15 ± 3
Albumin (g/dL) 3.5 ± 0.2 3.3 ± 0.3 3.2 ± 0.2 3.2 ± 0.298
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pathology. Thus this animal model has limited 
applicability for the study of experimental therapy 
of HIBM. In spite of absence of a relevant animal 
model, the specific detection of human GNE 
mRNA in mouse tissues after a single IM injection 
is a potentially promising ﬁ  rst step towards HIBM2 
gene therapy.
Prior studies have shown that GNE mutation 
probably affects the functional status, and not 
total protein expression of the GNE gene.
37 
HIBM2 patients and normal control subjects 
demonstrated similar levels of GNE expression 
by western blot and immunohistochemistry, 
although neither technique can discriminate 
between wild type vs. mutant GNE. In our studies 
GNE expression was analyzed using real-time 
qPCR, which is highly sensitive and speciﬁ  c for 
the human wild type recombinant GNE gene. 
Using this technique we were able to detect up to 
femtograms of the rGNE mRNA in the mouse 
tissues, based on speciﬁ  c primers that uniquely 
amplify the human GNE transcript (recombinant 
GNE mRNA transgene). Functional assays are 
currently under development to conﬁ  rm enhanced 
enzymatic activity.
AAV viruses have been used for IV injection 
to deliver transgenic DNA systemically to most 
skeletal muscles in neonatal dogs.
38 Unfortunately, 
most viral vectors can not be injected repeatedly 
due to the immunogenicity of the virus. Cationic 
DOTAP:Cholesterol liposomes are the most 
commonly used liposomes for gene delivery in 
various research and clinical studies. One of the 
advantages of using these liposomes is that their 
low immunogenicity allows for repeated injec-
tions to achieve maximum and long term expres-
sion in vivo.
39 Mouse muscle tissue was the third 
highest tissue in terms of CAT reporter gene 
expression when mice were injected intravenously 
with DOTAP:Chol complexed with the CAT 
reporter plasmid.
31 This formulation of liposomes 
has been shown to penetrate several tight layers 
of smooth muscle cells in the arteries of pigs
40 and 
has been used for gene delivery of various tumor 
suppressor genes with evidence of effectiveness 
in treatment of primary and disseminated lung 
cancers.
41,42
There are currently no effective treatments for 
HIBM2 patients. In our studies, we have demon-
strated reconstitution of enzymatically active protein 
in vitro
19 and recombinant GNE mRNA expression 
in muscles injected with 10 or 40 μg GNE-lipoplex. 
However, we were not able to demonstrate sialic 
acid reconstitution in this study because of the pres-
ence of endogenous, wild type activity in the 
experimental host. Functionally, the wild type GNE 
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Figure 3. Kaplan-Meier survival analysis for mice administered a single intravenous injection of GNE-lipoplex. Mice were administered a 
single intravenous injection of 0 μg, 10 μg, 40 μg, or 100 μg GNE-lipoplex. Survival was observed over 2 weeks. Four of 12 mice in 100 μg 
GNE-lipoplex cohort died within 24 hours after injection. The remaining eight mice in the 100 μg GNE-lipoplex cohort and 2 mice in 40 μg 
GNE-lipoplex cohort showed acute toxicity (rufﬂ  ed coat, hunched posture) within 24 hr of IV injection, but recovered within 48 hours and 
survived for 2 weeks.99
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enzyme is autoregulated by its downstream product, 
CMP-sialic acid.
43 Therefore, over-expression of 
the recombinant GNE transgene in the mouse tissues 
would not correspond to an over-expression of sialic 
acid. New animal studies are currently under way 
utilizing the M712T knock-in mice mentioned 
above. These animals will be injected with 
GNE-Lipoplex and monitored to determine if the 
animals survive beyond day 3 after birth. This 
animal model will not immediately address the 
efﬁ  cacy of the wild type GNE for rescued mus-
cle function, but will assess the safety of the 
GNE-Lipoplex and ability of the transgene to rescue 
the animal from the knock-in mutation.
Since reconstitution with sialic acid or Man-
NAc increased sialyation of proteins in various 
studies,
33,35,44 actually replacing the defective gene 
in human muscle with its wild type counterpart is 
hypothesized to be beneﬁ  cial to patients. This is 
anticipated to improve patient’s muscle function 
primarily as a result of resialyation of muscle pro-
teins but other GNE-mediated mechanisms may 
contribute.
Disclosure
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